Skip to main content
SpringerLink
Log in
Book cover

Leitlinien neuroleptischer Therapie pp 25–48Cite as

Bedeutung der Pharmakokinetik für die neuroleptische Behandlung am Beispiel von Fluphenazin

  • Conference paper

  • 24 Accesses

Zusammenfassung

Neuroleptika gelten als Pharmaka mit relativ großer therapeutischer Breite. Vor allem zur Akuttherapie schizophrener Erkrankungen werden sehr unterschiedlich hohe Dosen verwendet, während die für die Erhaltungstherapie empfohlenen Dosen niedriger liegen und weniger divergieren (z. B. Baldessarini u. Davis 1980; Aschauer u. Resch 1983). In vergleichenden Studien mit akuten Patienten stellte sich keine Überlegenheit hoher oder sehr hoher Dosen gegenüber mittleren heraus, während die Erfolge mit niedrigen Dosen geringer waren (Baldessarini et al. 1988). Ferner wurde beobachtet, daß individuell optimale Dosen sich von Patient zu Patient erheblich unterscheiden können (Davis u. Casper 1977).

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Altamura AC, Curry SH, Montgomery S, Wiles DH (1985) Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. Psychopharmacology 87:30–33

    Article  PubMed  CAS  Google Scholar 

  • Aschauer H, Resch F (1983) Praxisnahe Übersicht der Psychopharmaka mit Verzeichnis der Präparate. In: Langer G, Heimann H (Hrsg) Psychopharmaka. Grundlagen und Therapie. Springer, Wien New York, S 663–730

    Google Scholar 

  • Baldessarini RJ, Davis JM (1980) What is the best maintenance dose of neuroleptics in schizophrenia? Psychiatry Res 3:115–122

    Article  PubMed  CAS  Google Scholar 

  • Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45:79–91

    Article  PubMed  CAS  Google Scholar 

  • Bolvig Hansen L, Larsen NE (1985) Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology 87:16–19

    Article  Google Scholar 

  • Boza RA, Milanes F, Starkey T, Slater V, Dominguez F (1988) Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view. J Clin Psychiatry 49:245

    PubMed  CAS  Google Scholar 

  • Breyer U, Gaertner HJ, Prox A (1974) Formation of identical metabolites from piperazine- and dimethylamino-substituted phenothiazine drugs in man, rat and clog. Biochem Pharmacol 23:313–322

    Article  PubMed  CAS  Google Scholar 

  • Breyer-Pfaff U (1983) Klinische Pharmakokinetik der Neuroleptika. In: Langer G, Heimann H (Hrsg) Psychopharmaka. Grundlagen und Therapie. Springer, Wien New York, S 251–258

    Google Scholar 

  • Breyer-Pfaff U (1987) Klinische Pharmakokinetik der Neuroleptika: Ergebnisse und Probleme. In: Pichot P, Möller HJ (Hrsg) Neuroleptika. Rückschau 1952–1986. Künftige Entwicklungen. Springer, Berlin Heidelberg New York Tokyo (Tropon-Symposium II, S 37–46)

    Google Scholar 

  • Brown WA, Silver MA (1985) Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate. J Clin Psychopharmacol 5:143–147

    PubMed  CAS  Google Scholar 

  • Chang SS, Javaid JI, Dysken MW, Casper RC, Janicak PG, Davis JM (1985) Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia. Psychopharmacology 87:55–58

    Article  PubMed  CAS  Google Scholar 

  • Chouinard G, Jones BD (1980) Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 137:16–21

    PubMed  CAS  Google Scholar 

  • Chouinard G, Creese I, Boisvert D, Annable L, Bradwejn J, Jones B (1982) High neuroleptic plasma levels in patients manifesting supersensitivity psychosis. Biol Psychiatry 17:849–852

    PubMed  CAS  Google Scholar 

  • Cohen BM, Waternaux C, Chouinard G, Sommer BR, Jones B (1985) Plasma levels of neuroleptic in patients receiving depot fluphenazine. J Clin Psychopharmacol 5:328–332

    PubMed  CAS  Google Scholar 

  • Cooper JK, Hawes EM, Hubbard JW, McKay G, Midha KK (1989) An ultrasensitive method for the measurement of fluphenazine in plasma by high-performance liquid chromatography with coulometric detection. Ther Drug Monit 11:354–360

    Article  PubMed  CAS  Google Scholar 

  • Creese I, Snyder SH (1977) A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 270:180–182

    Article  PubMed  CAS  Google Scholar 

  • Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (1979) Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol 7:325–331

    PubMed  CAS  Google Scholar 

  • Dahl SG (1986) Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin Pharmacokinet 11:36–61

    Article  PubMed  CAS  Google Scholar 

  • Davis CM, Fenimore DC (1983) Determination of fluphenazine in plasma by high-performance thin-layer chromatography. J Chrom 272:157–165

    Article  CAS  Google Scholar 

  • Davis JM, Casper R (1977) Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs 14:260–282

    Article  PubMed  CAS  Google Scholar 

  • Dencker S J, Johansson R, Malm U (1988) Pharmacokinetic and pharmacodynamic studies on high doses of fluphenazine. Psychopharmacology 94:237–241

    Article  PubMed  CAS  Google Scholar 

  • Dreyfuss J, Ross Jr JJ, Shaw JM, Miller I, Schreiber EC (1976) Release and elimination of 14C-fluphenazine enanthate and decanoate esters administered in sesame oil to dogs. J Pharm Sci 65:502–507

    Article  PubMed  CAS  Google Scholar 

  • Dysken MW, Javaid JI, Chang SS, Schaffer C, Shahid A, Davis JM (1981) Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology 73:205–210

    CAS  Google Scholar 

  • Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR (1984) Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 45[Suppl2]:50–59

    PubMed  CAS  Google Scholar 

  • Ereshefsky L, Jann MW, Saklad SR, Davis CM (1986) Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview. J Clin Psychiatry 47 [Suppl]:6–15

    PubMed  CAS  Google Scholar 

  • Fairbairn AF, Rowell FJ, Hui SM, Hassanyeh F, Robinson AJ, Eccleston D (1983) Serum concentration of depot neuroleptics in tardive dyskinesia. Br J Psychiatry 142:579–583

    Article  PubMed  CAS  Google Scholar 

  • Garver DL (1989) Neuroleptic drug levels and antipsychotic effects: a difficult correlation; potential advantage of free (or derivative) versus total plasma levels. J Clin Psychopharmacol 9:277–281

    Article  PubMed  CAS  Google Scholar 

  • Gitlin MJ, Midha KK, Fogelson D, Nuechterlein K (1988) Persistence of fluphenazine in plasma after decanoate withdrawal. J Clin Psychopharmacol 8:53–56

    Article  PubMed  CAS  Google Scholar 

  • Glazer WM (1988) Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesia. Schizophrenia Res 1: 425–429

    Article  CAS  Google Scholar 

  • Goldstein SA, Van Vunakis H (1981) Determination of fluphenazine, related phenothiazine drugs and metabolites by combined high-performance liquid chromatography and radioimmunoassay. J Pharmacol Exp Ther 217:36–43

    PubMed  CAS  Google Scholar 

  • Harris PQ, Friedman M J, Cohen BM, Cooper TB (1982) Fluphenazine blood levels and clinical response. Biol Psychiatry 17:1123–1130

    PubMed  CAS  Google Scholar 

  • Hitzemann RJ, Garver DL, Mavroidis M, Hirschowitz J, Zemlan FP (1986) Fluphenazine activity and antipsychotic response. Psychopharmacology 90:270–273

    Article  PubMed  CAS  Google Scholar 

  • Hoffman DW, Edkins RD, Shillcutt SD, Salama A (1987) New high-performance liquid chromatographic method for fluphenazine and metabolites in human plasma. J Chrom Biomed Appl 414:504–509

    Article  CAS  Google Scholar 

  • Hoffman DW, Shillcutt SD, Edkins RD (1989) Measurement of blood levels of neuroleptics and metabolites by combined high performance liquid chromatography-radioreceptor assay for D2 and sigma sites. Biochem Pharmacol 38:831–836

    Article  PubMed  CAS  Google Scholar 

  • Javaid JI, Pandey GN, Duslak B, Hu HY, Davis JM (1980) Measurement of neuroleptic concentrations by GLC and radioreceptor assay. Commun Psychopharmacol 4:467–475

    PubMed  CAS  Google Scholar 

  • Jayaram G, Coyle J, Tune L (1986) Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels. J Clin Psychiatry 47:247–248

    PubMed  CAS  Google Scholar 

  • Jemal M, Ivashkiv E, Both D, Koski R, Cohen AI (1987) Picogram level determination of fluphenazine in human plasma by automated gas chromatography/mass selective detection. Biomed Environ Mass Spectrom 14:699–704

    Article  PubMed  CAS  Google Scholar 

  • Johansson R, Borg KO, Gabrielsson M (1976) Determination of fluphenazine in plasma by ion-pair partition chromatography. Acta Pharm Suec 13:193–200

    PubMed  CAS  Google Scholar 

  • Jørgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. Progr Drug Metab 9:111–174

    Google Scholar 

  • Kissling W, Möller HJ, Walter K, Wittmann B, Krueger R, Trenk D (1985) Double-blind comparison of haloperidol decanoate and fluphenazine decanoate: effectiveness, side-effects, dosage and serum levels during a six months’ treatment for relapse prevention. Pharmacopsychiatry 18:240–245

    Article  PubMed  CAS  Google Scholar 

  • Knudsen P, Bolvig Hansen L, Auken G, Waehrens J, Højholt K, Larsen NE (1985 a) Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients. Acta Psychiatr Scand 72 [Suppl 322]: 15–28

    Article  Google Scholar 

  • Knudsen P, Bolvig Hansen L, Højholt K, Larsen NE (1985 b) Long-term depot neuroleptic treatment with perphenazine decanoate I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients. Acta Psychiatr Scand 72 [Suppl 322]:29–40

    Article  Google Scholar 

  • Ko GN, Korpi ER, Linnoila M (1985) On the clinical relevance and methods of quantification of plasma concentrations of neuroleptics. J Clin Psychopharmacol 5:253–262

    Article  PubMed  CAS  Google Scholar 

  • Mailman RB, DeHaven DL, Halpern EA, Lewis MH (1984) Serum effects confound the neuroleptic radioreceptor assay. Life Sci 34:1057–1064

    Article  PubMed  CAS  Google Scholar 

  • Marder SR, Hawes EM, Van Putten T, Hubbard JW, McKay G, Mintz J, May PRA, Midha KK (1986) Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. Psychopharmacology 88:480–483

    Article  PubMed  CAS  Google Scholar 

  • Marder SR, Hubbard JW, Van Putten T, Midha KK (1989) Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications. Psychopharmacology 98:433–439

    Article  PubMed  CAS  Google Scholar 

  • Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1984) Therapeutic blood levels of fluphenazine: plasma or RBC determinations? Psychopharmacol Bull 20:168–170

    PubMed  CAS  Google Scholar 

  • McKay G, Hall K, Edom R, Hawes EM, Midha KK (1983) Subnanogram determination of fluphenazine in human plasma by gas chromatography mass spectrometry. Biomed Mass Spectrom 10:550–555

    Article  PubMed  CAS  Google Scholar 

  • Midha KK, Cooper JK, Hubbard JW (1980) Radioimmunoassay for fluphenazine in human plasma. Commun Psychopharmacol 4:107–114

    PubMed  CAS  Google Scholar 

  • Midha KK, McKay G, Edom R, Korchinski ED, Hawes EM, Hall K (1983) Kinetics of oral fluphenazine disposition in humans by GC-MS. Eur J Clin Pharmacol 25:709–711

    Article  PubMed  CAS  Google Scholar 

  • Midha KK, Hawes EM, Hubbard JW, Korchinski ED, McKay G (1988) Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients. Psychopharmacology 96:206–211

    Article  PubMed  CAS  Google Scholar 

  • Norman TR, Marriot PF, Kimber NM, Burrows GD (1987) Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals. Int Clin Psychopharmacol 2:299–305

    Article  PubMed  CAS  Google Scholar 

  • Schulz P, Rey MJ, Dick P, Tissot R (1989) Guidelines for the dosage of neuroleptics. Int Clin Psychopharmacol 4:105–114

    Article  PubMed  CAS  Google Scholar 

  • Svendson O, Dencker SJ, Fog R, Gravem AO, Kristjansen P (1980) Evidence of lymphogenic absorption of oil in humans receiving neuroleptic oily depot preparations intramuscularly. Acta Pharmacol Toxicol 47:157–158

    Article  Google Scholar 

  • Tjaden UR, Lankelma J, Poppe H, Muusze RG (1976) Anodic coulometric detection with a glassy carbon electrode in combination with reversed-phase high-performance liquid chromatography. Determination of blood levels of perphenazine and fluphenazine. J Chrom 125:275–286

    Article  CAS  Google Scholar 

  • Turbott J, Villiger J, Hunter L (1987) Depot neuroleptic medication and serum levels by radioreceptor assay: prolactin concentration, electrocardiogram abnormalities and six-month outcome. Aust NZJ Psychiatry 21:327–338

    CAS  Google Scholar 

  • Van Putten T, May PRA, Jenden DJ (1981) Dose a plasma level of chlorpromazine help? Psychol Med 11:729–734

    Article  PubMed  Google Scholar 

  • Van Putten T, Marder SR, Mintz J, Poland RE (1988) Haloperidol plasma levels and clinical response: a therapeutic window relationship. Psychopharmacol Bull 24:172–175

    PubMed  Google Scholar 

  • Viala A, Hou N, Ba B, Durand A, Dufour H, D’Agostino N, Berda C, Jørgensen A (1984) Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters. Psychopharmacology 83:147–150

    Article  PubMed  CAS  Google Scholar 

  • Whelpton R, Curry SH (1976) Methods for study of fluphenazine kinetics in man. J Pharm Pharmacol 28:869–873

    Article  PubMed  CAS  Google Scholar 

  • Wiles DH, Franklin M (1978) Radioimmunoassay for fluphenazine in human plasma. Br J Clin Pharmacol 5:265–268

    PubMed  CAS  Google Scholar 

  • Wiles DH, Gelder MG (1979) Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injection of fluphenazine decanoate. Br J Clin Pharmacol 8:565–570

    PubMed  CAS  Google Scholar 

  • Wilkins JN, Marder SR, Van Putten T, Midha KK, Mintz J, Setoda D, May PRA (1987) Circulating prolactin predicts risk of exacerbation in patients on depot fluphenazine. Psychopharmacol Bull 23:522–525

    Google Scholar 

  • Wistedt B, Jørgensen A, Wiles D (1982) A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology 78:301–304

    Article  PubMed  CAS  Google Scholar 

  • Yadalam KG, Simpson GM (1988) Changing from oral to depot fluphenazine. J Clin Psychiatry 49:346–348

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Toxikologie, Universität Tübingen, Wilhelmstr. 56, D-7400, Tübingen, Deutschland

    Prof. Dr. Dr. Ursula Breyer-Pfaff

Authors
  1. Prof. Dr. Dr. Ursula Breyer-Pfaff
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik, Rheinische Landesklinik, Heinrich-Heine-Universität, Bergische Landstr. 2, 4000, Düsseldorf 12, Deutschland

    Kurt Heinrich

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Breyer-Pfaff, U. (1990). Bedeutung der Pharmakokinetik für die neuroleptische Behandlung am Beispiel von Fluphenazin. In: Heinrich, K. (eds) Leitlinien neuroleptischer Therapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93466-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93466-7_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-52723-7

  • Online ISBN: 978-3-642-93466-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation